Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

Chronic Stent Recoil and Its Long-Term Effects

The evolution of stent technology—including new scaffold designs, thinner struts, and more biocompatible polymers—has brought about an emerging concern: the late loss of structural support, also known as chronic recoil.

This phenomenon, which was rarely reported in the era of first-generation stents, appears to have a non-negligible incidence with current devices. In response to this, Sugizaki et al. conducted a single-center observational study (at St. Francis Hospital in New York) using optical coherence tomography (OCT) intravascular imaging to quantify the phenomenon and assess its clinical impact.

The study included 265 de novo lesions (in 252 patients), all treated with second- or newer-generation stents. Chronic recoil was defined as either a >10-% reduction in stent volume over a 10-mm segment or a ≥10-% reduction in luminal area in cases of stent fracture or deformation.

Chronic recoil was identified in 21.5% of lesions that required target lesion revascularization (TLR), compared to only 7.8% of lesions that did not. Among the lesions with recoil, 41.9% were associated with stent fracture or deformation.

Read also: PROSPECT II Substudy: Relationship Between Different Levels of hs-CRP and Vulnerable Plaque Characteristics in Patients with NSTEMI.

In a multivariate analysis, the independent predictors of chronic recoil were greater calcium arc (odds ratio [OR] 1.64, 95% confidence interval [CI]: 1.17–2.29), greater baseline stent expansion (every 10-% increase: OR 1.41, 95% CI: 1.19–1.83), and higher stent eccentricity index (OR 0.61, 95% CI: 0.39–0.92).

Recoil was significantly associated with the need for TLR. In the predictive model for TLR, independent factors included smaller stent area at follow-up (OR 3.86, 95% CI: 1.57–9.48), increase in intra-stent tissue area (OR 4.26, 95% CI: 2.83–6.41), and lower final baseline minimum stent area (MSA) (OR 0.38, 95% CI: 0.28–0.51).

Read also: iVAC2L: New Contribution to Ventricular Assist Devices in High Risk PCIs.

Notably, in 58% of the cases with recoil there was no evidence of fracture or structural deformation, highlighting the usefulness of OCT in detecting this subclinical phenomenon. These findings underscore the importance of achieving uniform and complete stent expansion during the procedure, especially in cases of extensive calcified plaque or eccentric lesions.

Conclusions

Chronic stent recoil is a significant mechanism of target lesion revascularization with meaningful clinical consequences. This study highlights the importance of morphological assessment with OCT to improve long-term outcomes of percutaneous coronary intervention (PCI).

Original Title: Factors Associated With Chronic Stent Recoil and its Impact on Revascularization.

Reference: Sugizaki Y, Chen YW, Tsukui T, Kido T, Matsumura M, Shlofmitz E, Sosa FA, Shin D, Cannata M, Caron E, Ciftcikal Y, Moses JW, Khalique OK, Cohen DJ, Mintz GS, Shlofmitz RA, Jeremias A, Ali ZA, Maehara A. Factors Associated With Chronic Stent Recoil and its Impact on Revascularization: A Serial Optical Coherence Tomography Study. JACC Cardiovasc Interv. 2025 May 12;18(9):1133-1144. doi: 10.1016/j.jcin.2025.01.432. Epub 2025 Apr 23. PMID: 40272344.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

 

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

EuroPCR 2026 | Is It Safe to Stop Aspirin After One Month in MI Patients Undergoing PCI? TARGET-FIRST Analysis

This is a summary of the post-hoc analysis of the TARGET-FIRST study, presented by Dr. Giuseppe Tarantini at EuroPCR 2026, evaluating early aspirin discontinuation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

EuroPCR 2026 | TAVI in Women: Do Supra-Annular Valves Offer a True Hemodynamic Advantage?

Women represent a particularly challenging population for TAVI, as they often have smaller aortic annuli, greater frailty, and an increased risk of prosthesis-patient mismatch....

EuroPCR 2026 | TAVI or Surgery in Younger Patients? Quality of Life and 3-Year Outcomes from NOTION-2

The expansion of TAVI into younger and lower surgical-risk populations has sparked a new debate: beyond mortality and stroke, which strategy provides better functional...

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...